Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1993; 22:891-898
© 1993 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moe, G.
Right arrow Articles by Armstrong, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moe, G.
Right arrow Articles by Armstrong, P.

Dual natriuretic peptide system in experimental heart failure

GW Moe, EA Grima, NL Wong, RJ Howard, and PW Armstrong

Department of Medicine, St. Michael's Hospital, University of Toronto, Ontario, Canada.

OBJECTIVES. The objectives of this study were 1) to define in an experimental model of heart failure the time course of changes in plasma brain natriuretic peptide concentrations during the development of and recovery from heart failure, and 2) to relate the changes to changes in atrial natriuretic peptide concentration and hemodynamic status. BACKGROUND. Brain natriuretic peptide is a circulating peptide with homology to atrial natriuretic peptide. However, unlike the latter, its changes during heart failure and its relation to cardiac filling pressures have not been studied. METHODS. Eight male mongrel dogs underwent right ventricular pacing at 250 beats/min for 3 weeks until heart failure occurred and were followed up during recovery for 4 weeks after cessation of pacing. RESULTS. Heart failure was characterized by an increase in both left ventricular and end-diastolic pressure (6.6 +/- 4.1 mm Hg at the control measurements to 35.1 +/- 5.9 mm Hg at 3 weeks, p < 0.01) and right atrial pressure (6.7 +/- 1.1 to 11.4 +/- 2.1 mm Hg, p < 0.01). Recovery was accompanied by a return of cardiac filling pressures to control level. The time course of change of arterial plasma brain natriuretic peptide concentration was similar to that of atrial natriuretic peptide. Plasma concentrations of both peptides increased after 1 week of pacing (16 +/- 4 pg/ml at the control measurement to 59 +/- 20 pg/ml at 1 week, p < 0.001 for brain natriuretic peptide and 84 +/- 55 to 856 +/- 295 pg/ml, p < 0.001 for atrial natriuretic peptide). The level of both peptides then stayed level with no further increase at 3 weeks and returned to the control value by 4 weeks of recovery. There was an excellent correlation between plasma concentrations of the two peptides (r = 0.86, p < 0.001) and between the two peptides and cardiac filling pressures. However, compared with atrial natriuretic peptide, plasma brain natriuretic peptide concentration had a smaller percent increase during evolving heart failure and a slower rate of decline at recovery. CONCLUSIONS. Brain and atrial natriuretic peptide constitute a dual natriuretic system and are both responsive to changes in cardiac filling pressures in heart failure. However, brain natriuretic peptide appears to be less responsive than atrial natriuretic peptide.


This article has been cited by other articles:


Home page
J Histochem CytochemHome page
G. M. Bialik, Z. A. Abassi, I. Hammel, J. Winaver, and D. Lewinson
Evaluation of Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Atrial Granules of Rats with Experimental Congestive Heart Failure
Journal of Histochemistry & Cytochemistry, October 1, 2001; 49(10): 1293 - 1300.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A.J. Drake-Holland and M.I.M. Noble
Neural-natriuretic hormone interactions
Eur. Heart J., March 2, 2000; 21(6): 424 - 426.
[PDF]


Home page
Cardiovasc ResHome page
G. W Moe and P. Armstrong
Pacing-induced heart failure: a model to study the mechanism of disease progression and novel therapy in heart failure
Cardiovasc Res, June 1, 1999; 42(3): 591 - 599.
[Full Text] [PDF]


Home page
CirculationHome page
L. S. Marcus, D. Hart, M. Packer, M. Yushak, N. Medina, R. S. Danziger, D. F. Heitjan, and S. D. Katz
Hemodynamic and Renal Excretory Effects of Human Brain Natriuretic Peptide Infusion in Patients With Congestive Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Crossover Trial
Circulation, December 15, 1996; 94(12): 3184 - 3189.
[Abstract] [Full Text]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement